These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16083329)

  • 1. The development of erythropoietic agents in oncology.
    Glaspy JA
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):553-67. PubMed ID: 16083329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin beta therapy in patients with solid tumours.
    Pronzato P; Jassem J; Mayordomo J
    Crit Rev Oncol Hematol; 2006 Apr; 58(1):46-52. PubMed ID: 16169242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 7. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin in cancer: presumption of innocence?
    Blau CA
    Stem Cells; 2007 Aug; 25(8):2094-7. PubMed ID: 17464082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
    Gondek K; Sagnier PP; Gilchrist K; Woolley JM
    J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinued drugs in 2008: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
    Chan A; Lim LL; Tao M
    Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke.
    Edwards G
    Drug Discov Today; 2005 Nov; 10(22):1491-4. PubMed ID: 16257369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.